SCHEMBL24508317

SCHEMBL24508317

Cc1c(Br)ccn2c(I)cnc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23089200 0.83 CCR1 (0.32)
SCHEMBL20985967 0.81 KDM4E (0.34)
SCHEMBL23089765 0.80
SCHEMBL24508618 0.80 EGFR (0.33)
SCHEMBL23104252 0.73
SCHEMBL24780130 0.68 DYRK1B (0.34)
SCHEMBL25045595 0.67 KDM4E (0.36)
SCHEMBL20049573 0.67 MAPT (0.33)
SCHEMBL23104791 0.66 IKBKB (0.33)
SCHEMBL20919583 0.66 CDK4 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4259128-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-10-18 EP disclosed
CN-116669722-A Interleukin-1 receptor-related kinase (IRAK) degradants and uses thereof 凯麦拉医疗公司 2023-08-29 CN disclosed
WO-2022125790-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-06-16 WO disclosed
WO-2022125790-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-06-16 WO disclosed